{"id":"W2797132528","doi":"10.1016/j.jaad.2018.04.012","title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":155,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Clinical trial; Dermatology; Adalimumab; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01159638,0.001515637,0.002474185,0.0006366704,0.0006060494,0.001157345,0.0007834175,0.002191576,0.003722474],"category_scores_gemma":[0.005654512,0.000578046,0.003838627,0.0005997519,0.0007486402,0.001059163,0.0004719329,0.00224745,0.0005269779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008361206,"about_ca_system_score_gemma":0.001634719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006034861,"about_ca_topic_score_gemma":0.001244357,"domain_scores_codex":[0.9976809,0.001229497,0.0002771095,0.0003081995,0.0003066048,0.0001976005],"domain_scores_gemma":[0.9957358,0.001283989,0.001600383,0.00031083,0.0004939302,0.0005751354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.799189,0.01297939,0.005262691,0.004770923,0.007998942,0.000146773,0.0003079219,0.0009721422,0.01929508,0.0001612712,0.003056166,0.1458596],"study_design_scores_gemma":[0.8145604,0.1520492,0.02058806,0.0004971924,0.004375374,0.0002448922,0.00004628203,0.0004143493,0.003462698,0.0001674105,0.003546603,0.0000475214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9151005,0.06598678,0.002659822,0.001781508,0.0004955205,0.008031189,0.002779177,0.0003231368,0.002842464],"genre_scores_gemma":[0.9619821,0.02088878,0.005238699,0.001938332,0.000656025,0.005246606,0.002569408,0.00008411754,0.00139588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01159638,"threshold_uncertainty_score":0.06132823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04701122508122613,"score_gpt":0.3529104809531127,"score_spread":0.3058992558718866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}